Yuee Teng
First Hospital of China Medical University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yuee Teng as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:48 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04400695 · A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RemeGen Co., Ltd. · recruiting · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:48 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases.Cell Rep · 2012246 citationsRCR 5.8
- 232 citationsRCR 6.7
- 153 citationsRCR 6.8
- Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.Nat Med · 2024134 citationsRCR 14.2
- 108 citationsRCR 8.6
- 107 citationsRCR 9.1
- Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.Nat Med · 202568 citationsRCR 13.1
- 67 citationsRCR 4.3
- 57 citationsRCR 1.5
- 44 citationsRCR 2.1